Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Canada
Deutschland
España
France
Italia
Schweiz (DE)
Suisse (FR)
United Kingdom
United States
Settings
Dynamic quotes
OFF
ON
Markets
Equities
North America
Europe
Asia
Oceania
Middle East
»
More Equities
Indexes
DOW JONES
S&P 500
NASDAQ 100
TSX COMP
NIKKEI 225
»
More Indexes
Currency / Forex
EUR / USD
GBP / USD
USD / JPY
USD / CAD
AUD / USD
»
More Currencies
Commodities
GOLD
Crude Oil (WTI)
Crude Oil (BRENT)
SILVER
PLATINUM
»
More Commodities
Trackers & ETF
Rankings and News
Advanced Search
Cryptocurrencies
BITCOIN
ETHEREUM
News
Latest News
Companies
Markets
Economy
Currency / Forex
Commodities
Interest Rates
Business Leaders
Cryptocurrencies
Cybersecurity
Economic calendar
Listed companies
Analyst reco.
Rumors
IPOs
Capital Markets Transactions
New Contracts
Profit warnings
Appointments
Press Releases
Events
Corporate actions
Financial calendar
Sector News
Energy
Basic Materials
Industrials
Consumer Cyclical
Consumer Non-Cyclical
Financials
Healthcare
Technology
Telecommunications Services
Utilities
Analysis
All Analysis
Must Read
Daily briefing
Weekly market update
Stock Trading Strategies
Stock Picks
All stock picks
Subscribe
Portfolios
My Portfolio
Virtual portfolios
MarketScreener Portfolios
USA Portfolio
European Portfolio
Asian Portfolio
Watchlists
My Watchlists
Watchlists
My previous session
My most visited
Most popular
Investment style
Yield stocks
Growth stocks
Undervalued Stocks
Investment themes
Water
Sin stocks
Biotechnology
At the foot of the Mont Blanc
Place your bets
Europe's family businesses
Let’s all cycle!
Fintechs
Ageing Population
Top / Flop
Top News
Most Read News
Hot News
Top Fundamentals
Top Capitalization
Top Yield
Top PER
Top Consensus
Top Fundamentals
Top Technicals
Top RSI
Unusual volumes
Top Gaps
Top STIM
Breakouts
Trends
Top Movers
Top USA
Top Canada
Top U.K.
Top Germany
Top Europe
Top Asia
Screeners
Investment selections
Water
Sin stocks
Biotechnology
At the foot of the Mont Blanc
Place your bets
Europe's family businesses
Technical Rankings
Oversold stocks
Overbought stocks
Close to resistance
Close to support
Accumulation Phases
Most volatile stocks
Fundamental Rankings
Top Investor Rating
Top Trading Rating
Top Consensus
Growth stocks
Yield stocks
Low valuations
Stock Screener Home
My Screeners
All my stocks
Watchlists
Virtual Portfolios
Tools
MarketScreener tools
Stock Screener
iPhone App
Expert tools
Stock Screener PRO
Portfolio Creator
Event Screener
Dynamic chart
Financial calendar
Economic calendar
Sector research
Currency converter
ProRealTime Trading
Our Services
MarketScreener Portfolios
European Portfolio
USA Portfolio
Asian Portfolio
Our Stock Picks
Thematic Investment Lists
Stock Screener
MarketScreener Homepage
>
Equities
>
Nyse
>
Merck & Co., Inc.
MRK
MERCK & CO., INC.
(MRK)
Add to my list
Report
Delayed Nyse -
01/26 04:10:00 pm
80.25
USD
-1.11%
01/26
MERCK
: Declares Unchanged Quarterly Dividend of $0.65 Per Common Share, Payable April 7 to Holders as of March 15
MT
01/26
MERCK
: Announces Second-Quarter 2021 Dividend
BU
01/26
MERCK
: Says Interim Findings From Ongoing Mid-Stage Study Show Potential of Islatravir for HIV-1 Infection Prevention
MT
Summary
Quotes
Charts
News
Ratings
Calendar
Company
Financials
Consensus
Revisions
Summary
Most relevant
All News
Analyst Reco.
Other languages
Press Releases
Official Publications
Sector news
MarketScreener Strategies
MERCK & CO., INC. : Ex-dividend day for
12/14/2020 EST
Send by mail :
Name :
First name :
From
*
:
To
*
:
(You can enter multiple email addresses separated by commas)
Message :
*
Required fields
A dividend is removed today from Merck & Co., Inc.'s share.
© Factset 2020
All news about MERCK & CO., INC.
01/26
MERCK
: Declares Unchanged Quarterly Dividend of $0.65 Per Common Share, Payable..
MT
01/26
MERCK
: Announces Second-Quarter 2021 Dividend
BU
01/26
MERCK
: Says Interim Findings From Ongoing Mid-Stage Study Show Potential of Isl..
MT
01/26
MERCK
: Presents Interim Findings from Phase 2a Clinical Trial Evaluating Invest..
BU
01/26
Merck Secures European Commission's Approval of Keytruda as Monotherapy of Co..
MT
01/26
MERCK
: European Commission Approves Keytruda in Some Colorectal Cancers
DJ
01/26
MERCK
: European Commission Approves KEYTRUDA® (pembrolizumab) as First-Line Tre..
BU
01/26
MERCK
: Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates, Cont..
AQ
01/25
Merck Scraps Covid-19 Vaccine Candidates -- Update
DJ
01/25
MERCK
: Correction to Merck Scraps Covid-19 Vaccine Candidates Article
DJ
More news
Financials (USD)
Sales 2020
48 203 M
-
-
Net income 2020
12 158 M
-
-
Net Debt 2020
15 159 M
-
-
P/E ratio 2020
16,9x
Yield 2020
3,05%
Capitalization
203 B
203 B
-
EV / Sales 2020
4,53x
EV / Sales 2021
4,17x
Nbr of Employees
71 000
Free-Float
70,7%
More Financials
Chart MERCK & CO., INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short Term
Mid-Term
Long Term
Trends
Neutral
Neutral
Neutral
Technical analysis
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
More Financials
Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Average target price
97,05 $
Last Close Price
80,25 $
Spread / Highest target
33,3%
Spread / Average Target
20,9%
Spread / Lowest Target
5,92%
Consensus
EPS Revisions
Please enable JavaScript in your browser's settings to use dynamic charts.
More Estimates Revisions
Managers and Directors
Name
Title
Kenneth C. Frazier
Chairman, President & Chief Executive Officer
Robert M. Davis
CFO & Executive Vice President-Global Services
Sandy Tremps
Vice President-R&D IT CIO
Thomas Henry Glocer
Independent Director
Leslie A. Brun
Lead Independent Director
More about the company
Sector and Competitors
1st jan.
Capitalization (M$)
MERCK & CO., INC.
-1.89%
203 035
JOHNSON & JOHNSON
8.32%
436 949
ROCHE HOLDING AG
3.82%
309 894
NOVARTIS AG
2.96%
220 401
PFIZER INC.
1.36%
207 217
ABBVIE INC.
3.13%
195 085
More Results
Master
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
